SRRK
Scholar Rock Holding Corp
NASDAQ · Healthcare · Biotechnology · US
$46.65
−4.83%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$48.02
From 52W high−22.30%
Volume3.20M
Market cap$5.68B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$48.02
From 52W high
−22.30%
Volume
3.20M
Market cap
$5.68B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.6x
P/E (TTM)
—
RSI (14)
29.5
MomentumView details →
1D Return
−4.83%
YTD Return
+4.23%
SummaryUpdated Jun 1, 2026
Scholar Rock Holding Corporation (NASDAQ:SRRK) is a Cambridge, Massachusetts-based biopharmaceutical company founded in 2012 that focuses on discovering and developing medicines targeting protein growth factor signaling pathways. The company went public in May 2018 and has emerged as a leader in developing highly selective inhibitors of latent growth factor activation, particularly targeting myostatin and transforming growth factor beta (TGF-β) pathways. Scholar Rock's lead drug candidate, apitegromab, recently completed successful Phase 3 clinical trials for treating spinal muscular atrophy and is currently under regulatory review by the FDA, with potential approval expected in September 2025.
Similar companies
Latest newsMore news →
Scholar Rock set a list price of $11,659 per single-use vial for its newly approved spinal muscular atrophy drug, the first therapy directly targeting muscle loss in patients with the rare genetic disorder.6d agoThe U.S. Food and Drug Administration approved Scholar Rock's therapy for a rare genetic condition that causes muscle weakness.9d agoScholar Rock resubmitted a biologics license application for apitegromab, its SMA treatment, supported by an alternate fill-finish manufacturing facility, with an FDA decision date of September 30.34d ago